Skip to main content
. Author manuscript; available in PMC: 2024 May 15.
Published in final edited form as: JCO Precis Oncol. 2024 Apr;8:e2300635. doi: 10.1200/PO.23.00635

FIG 5.

FIG 5.

OS (A) of all patients with Sig3-positive tumors who initiated protocol therapy and (B) after excluding patients who crossed over to gemcitabine/berzosertib and (C) of all patients with Sig3-negative tumors who initiated protocol therapy and (D) after excluding patients who crossed over to gemcitabine/berzosertib. HR, hazard ratio; OS, overall survival; Sig3, signature 3.